Semaglutide and tirzepatide
GLP-1 / GIP receptor agonists (semaglutide, tirzepatide). Diabetes & metabolic. Reviewed Jul 2026.
Large outcome trials show fewer cardiovascular events and kidney protection, with open questions on muscle loss and lifelong use.
What it is
Incretin-mimicking drugs that drive major weight loss and glucose control, increasingly shown to protect heart, kidney and possibly brain.
The evidence
Large outcome trials show reduced cardiovascular events and kidney protection; obesity and diabetes indications approved. Open questions on muscle loss and lifelong use.
What you can do today
This is available today. Whether it suits you depends on your health, your other medicines and your risks, so discuss it with a clinician who knows your history before starting or changing anything.
Sources
- Coverage, not a sourcehonehealth.com
No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.
Change history
No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.
Related
More in Diabetes & metabolic
All 3 in Diabetes & metabolic.
- Stem-cell islets for type 1 diabetes10 of 12 patients were off insulin at one year in an early trial, but it needs chronic immunosuppression and Phase 3 results are not out.
- RetatrutideTop doses cut body weight by about 28 to 30% in trials, but outcome trials are still running and it is not approved.